BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company announced its 4Q and full year 2024 results. The company continues to execute at a high level by posting record revenue and earnings that beat expectations.
